BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CREST - ECPv5.1.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CREST
X-ORIGINAL-URL:https://crest.science
X-WR-CALDESC:Events for CREST
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
BEGIN:DAYLIGHT
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:EEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:EET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Helsinki:20251008T121500
DTEND;TZID=Europe/Helsinki:20251008T133000
DTSTAMP:20260710T021130
CREATED:20250807T083828Z
LAST-MODIFIED:20250922T142152Z
UID:18279-1759925700-1759930200@crest.science
SUMMARY:Léa BIGNON (KU Leuven) - "Pharmaceuticals and Digital Health: How Data-driven Insights May Reshape the Insulin Market"
DESCRIPTION:Séminaire Microéconomie : Tous les mercredis\nHeure : 12h15 – 13h30\nDate :08/10/2025\nSalle : 3001 \nLéa BIGNON (KU Leuven) – “Pharmaceuticals and Digital Health: How Data-driven Insights May Reshape the Insulin Market” \nCV : Digital health technologies\, such as Continuous Glucose Monitors (CGMs)\, are transforming the availability of patient-level data\,potentially influencing healthcare markets more broadly. This paper examines how CGMs influence the insulin market\, shedding light on the impact of digital health technologies on pharmaceutical demand\, pricing\, and innovation incentives. I develop and estimate a tractable model of supply and demand for insulin\, embedding: (i) patient-specific learning about treatment performance through the digital device\, (ii) physician-level learning about new insulin products based on patient experiences\, and (iii) price bargaining by pharmaceutical companies and the regulator\, both internalizing demand-side learning. Using comprehensive medical claims data from France\, where expanded CGM coverage boosted technology adoption\, I find that CGMs’ patient-specific information steered insulin demand towards newer products\, with limited information spillover to nonusers. Manufacturers of drugs that benefited from higher perceived quality\, thanks to the observability of these attributes\, could negotiate higher drug prices. My findings indicate that the introduction of these new observable attributes into pharmaceutical demand can shift the relative profitability of drug innovation strategies\, thereby shaping future pharmaceutical innovation. \nOrganisateurs : \nJulien COMBE (Pôle d’Economie du CREST)\n​​​​​​​​​​​​Yves Le YAOUANQ (Pôle d’Economie du CREST)\n​​​​​​​​​Matias NUNEZ (Pôle d’Economie du CREST) \nCommanditaires :\nCREST \n
URL:https://crest.science/event/maxime-gravoueille-monash-university-tba/
CATEGORIES:Microeconomics,Seminars
ATTACH;FMTTYPE=:
END:VEVENT
END:VCALENDAR